Pharmaceutical

Kelburn Recovery Centre is pleased to announce that Dr. Ian Rabb addiction treatment and clinic operations veteran has recently joined as Managing Director.

Dr Ian Rabb recently named Chief Clinics Officer for Universal Ibogaine Inc ((TSXV: IBO), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, effective November 15 th 2021.  Universal Ibogaine acquired the Kelburn Clinic in October of 2021.

Kate Bloy , renowned addiction treatment psychotherapist and psychedelic therapy pioneer, has also joined the team at Kelburn as Clinical Director.

Did you know: That 1 in 5 Canadians are affected by addiction?

Dr Ian Rabb stated, "At Kelburn Recovery Centre, we recognize addiction is a treatable illness; we provide substance use and mental health treatment in a private setting to ensure confidentiality. We are committed to a holistic approach to healing. Mental, physical, emotional and spiritual health are considered in every program. Each guest receives trauma informed therapies & evidence-based treatments individualized for their own situation."

Kelburn covers a wide range of needs, from outpatient therapy to short-term detox stays and multi-month treatment for mental health and substance use disorders.

Dr Ian Rabb – Managing Director, Kelburn Recovery Centre/ Chief Clinic Officer, Universal Ibogaine Inc.

Dr Ian Rabb is one of the most recognized and respected leaders in Addiction Treatment in Canada today.  Dr. Ian Rabb is a certified Interventionist and addictions specialist who has helped thousands of people overcome addiction. In his 20 years of sobriety, he founded Two Ten Recovery and Destiny House Winnipeg's only sober living housing organization, was the founding member of Aurora Recovery Centre and most recently held the position of Director of Business Development at Edgewood Health Network, Canada's only national addiction treatment center brand.

Dr. Rabb has served on the board of directors of the Addictions Foundation of Manitoba,  he was Chair of a forum for VOICES, which provides services for transitioning foster youth. Ian led the Homelessness Task Force in 2014, served on the inaugural board of End Homelessness Winnipeg, and sat on the Community Advisory Board for The Homelessness Partnering Strategy. He has further played an active role on the board of the Jewish Child and Family Services, the Children's Hospital Foundation, and the Health Science Centre Foundation.

Did you know: Opioid overdose is the leading cause of death in people under 50?

Ian says "In my 20 years in the addiction recovery business I have not seen anything that has the power of Ibogaine to disrupt the devastating effects of addiction. The opportunity to join the leadership team of Universal Ibogaine and as managing director of Kelburn Recovery Centre, where we intend to revolutionize addiction treatment, was something I could not refuse."

Ian added, "We would like to thank Josephine D'Andrea for her years of dedication and work at Kelburn Recovery Centre. She has decided to move forward with her next endeavor."

Kate Bloy – Clinical Director, Kelburn Recovery

Kate Bloy has been a professional psychotherapist for 14 years and is the Founder and CEO of Therapeutic Alliance, a private therapy practice in Winnipeg, Manitoba . She has been working in the addictions field for over 12 years, heading up therapy programs in Manitoba including the St. Raphael Wellness Centre and the Aurora Treatment Centre as well as successfully treating people with addiction issues within her private practice.

Kate is a leader in the psychedelic psychotherapy field, serving as the President of the Psychedelic Society of Winnipeg and as Coordinator of Psychedelic Harm Reduction Services with Winnipeg Folk Festival. She studied the clinical use of psychedelics, including ibogaine, with organizations including Medicinal Mindfulness, Fluence, Mt. Tam Integration, Iboga Soul and the Multidisciplinary Association for Psychedelic Studies.

In her own words, Kate describes herself as "a guide, helping people connect with their inner healing wisdom and integrating these experiences to optimize their potential and well-being."

Clinic Inquiries, please contact: Dr. Ian Rabb
ian.rabb@kelburnrecoverycentre.com

About Kelburn Recovery Centre:
Conveniently located in St. Adolphe , 7 kms south of Winnipeg . Kelburn Recovery Centre is a unique executive property on 45 beautiful acres along the Red River, approx. 30 minutes from Winnipeg James Armstrong Richardson International Airport. Kelburn Recovery Centre is ideally located for visits by family and outings into the Winnipeg area.

  • A 10,000 square foot executive residential home with bedrooms for 10 guests
  • Indoor sauna, Games room, Great room and more
  • A 9 -hole PGA standard, Executive Golf Course designed by Golf Course Architect, David Grant
  • Strategically placed BBQ's, allowing for family visits
  • Three beautiful lakes and a brook with all seasons walking paths
  • The property is lined with mature oak and pine trees for confidentiality, privacy and beauty

SOURCE Universal Ibogaine Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/January2022/19/c8920.html

News Provided by Canada Newswire via QuoteMedia

IBO:CA
Universal Ibogaine

Universal Ibogaine


Keep reading... Show less
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022 .

Keep reading... Show less
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.

Keep reading... Show less
Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

(TheNewswire)

Universal Ibogaine Inc.

Calgary, AB TheNewswire - April 21, 2022 Universal Ibogaine Inc. ( TSXV:IBO ) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the UI Board of Directors to pursue other opportunities.

Keep reading... Show less
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

Universal Ibogaine Inc. (TSXV: IBO) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (" Kelburn ") due to an on-site flooding issue.

Keep reading... Show less
Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

 Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the " FSE ") under the ticker symbol " JC4 ".  UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker symbol IBOGF.

Keep reading... Show less
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc. ("Halucenex"), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.

Additionally, Optimi wishes to confirm that the supply agreement pertains to the entirety of the Company's recently harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies.

Keep reading... Show less
Albert Labs

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

Albert Labs Appoints Dr Sara Tai as Principal Investigator for upcoming RWE Study on KRN-101

Albert Labs International Corp. ( Albert Labs (CSE: ABRT) (FSE: VB50), the "Company"), an R&D company developing mental health therapeutic medicines, is pleased to announce Dr. Sara Tai Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for its upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress, an indication thought to affect some 15 million patients in Europe and North America .

Keep reading... Show less
two open palms hold a sphere representing the earth with water in the background

Sustainable Packaging: Increasing Demand for Natural Solutions

We only have one planet — and until recently we've done a poor job taking care of it.

The packaging industry is one of the sectors in which this is most evident. With a projected market size of US$1.13 trillion by 2030, it also represents one of the most significant sources of pollution in the world. Globally, we produce roughly 380 million tons of plastic per year. Single-use items such as grocery bags, bottles and packaging represent around 50 percent of that number.

To put this into context, the plastic waste produced by soft drink companies could cover 83 football fields a day, and the pollution footprint of packaging is at least as bad.

Keep reading... Show less
Billy Goat Brands CEO Tony Harris

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability youtu.be

Keep reading... Show less
Albert Labs

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada . This approval permits the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances within the confines of the regulations governing controlled substances.

Keep reading... Show less
Albert Labs

Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies

World-renowned scientists from the University of CESPU Health Sciences Department, Portugal are working in partnership with Albert Labs' expert team to conduct safety and toxicology studies, in preparation for KRN-101's use in Real World Evidence studies.

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical quality medicines, based on the mycelia of Psilocybe, today released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal . The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide.

Keep reading... Show less

Latest Press Releases

Related News

×